Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors
Royalty Pharma (RPRX) has appointed Dr. Vlad Coric to its Board of Directors, effective immediately. Dr. Coric, currently Chairman and CEO of Biohaven, brings over 20 years of drug discovery and clinical development experience from Yale School of Medicine and Bristol-Myers Squibb.
Under his leadership at Biohaven, Dr. Coric achieved significant milestones including:
- FDA approval and launch of Nurtec ODT for migraine treatment
- NDA filing for zavegepant, the first intranasal CGRP antagonist for migraine
- Led Biohaven's growth from founding through its $13 billion sale to Pfizer in May 2022
His expertise spans multiple therapeutic areas including neurology, psychiatry, immunology, virology, oncology and immuno-oncology. Dr. Coric completed his medical education at Wake Forest University and postdoctoral training at Yale School of Medicine.
Royalty Pharma (RPRX) ha nominato il Dott. Vlad Coric nel suo Consiglio di Amministrazione, con effetto immediato. Il Dott. Coric, attualmente Presidente e CEO di Biohaven, porta con sé oltre 20 anni di esperienza nella scoperta di farmaci e nello sviluppo clinico proveniente dalla Yale School of Medicine e da Bristol-Myers Squibb.
Sotto la sua guida in Biohaven, il Dott. Coric ha raggiunto traguardi significativi tra cui:
- Approvazione e lancio da parte della FDA di Nurtec ODT per il trattamento dell'emicrania
- Presentazione della NDA per zavegepant, il primo antagonista CGRP intranasale per l'emicrania
- Ha guidato la crescita di Biohaven dalla sua fondazione fino alla vendita di 13 miliardi di dollari a Pfizer nel maggio 2022
La sua esperienza copre diverse aree terapeutiche tra cui neurologia, psichiatria, immunologia, virologia, oncologia e immuno-oncologia. Il Dott. Coric ha completato la sua formazione medica presso la Wake Forest University e la formazione post-dottorato presso la Yale School of Medicine.
Royalty Pharma (RPRX) ha nombrado al Dr. Vlad Coric en su Junta Directiva, con efecto inmediato. El Dr. Coric, actualmente Presidente y CEO de Biohaven, aporta más de 20 años de experiencia en descubrimiento de fármacos y desarrollo clínico de la Escuela de Medicina de Yale y Bristol-Myers Squibb.
Bajo su liderazgo en Biohaven, el Dr. Coric logró hitos significativos, incluyendo:
- Aprobación y lanzamiento por parte de la FDA de Nurtec ODT para el tratamiento de la migraña
- Presentación de la NDA para zavegepant, el primer antagonista CGRP intranasal para la migraña
- Dirigió el crecimiento de Biohaven desde su fundación hasta su venta de 13 mil millones de dólares a Pfizer en mayo de 2022
Su experiencia abarca múltiples áreas terapéuticas, incluyendo neurología, psiquiatría, inmunología, virología, oncología e inmuno-oncología. El Dr. Coric completó su formación médica en la Universidad de Wake Forest y su formación postdoctoral en la Escuela de Medicina de Yale.
Royalty Pharma (RPRX)는 드. 블라드 코릭을 이사회에 즉시 임명했습니다. 현재 바이오헤븐의 회장 겸 CEO인 드. 코릭은 예일 의과대학과 브리스톨-마이어스 스큅에서 20년 이상의 약물 발견 및 임상 개발 경험을 가지고 있습니다.
바이오헤븐에서의 그의 리더십 아래, 드. 코릭은 다음과 같은 중요한 이정표를 달성했습니다:
- 편두통 치료를 위한 Nurtec ODT의 FDA 승인 및 출시
- 편두통을 위한 첫 번째 비강 CGRP 길항제인 자베게판에 대한 NDA 제출
- 2022년 5월 화이자에 130억 달러에 매각될 때까지 바이오헤븐의 성장을 이끌었습니다.
그의 전문성은 신경학, 정신의학, 면역학, 바이러스학, 종양학 및 면역종양학을 포함한 여러 치료 분야에 걸쳐 있습니다. 드. 코릭은 웨이크 포레스트 대학교에서 의학 교육을 마치고 예일 의과대학에서 박사후 연구를 수행했습니다.
Royalty Pharma (RPRX) a nommé le Dr Vlad Coric au sein de son Conseil d'Administration, avec effet immédiat. Le Dr Coric, actuellement Président et CEO de Biohaven, apporte plus de 20 ans d'expérience en découverte de médicaments et en développement clinique de la Yale School of Medicine et de Bristol-Myers Squibb.
Sous sa direction chez Biohaven, le Dr Coric a atteint des étapes significatives, notamment :
- Approbation et lancement par la FDA de Nurtec ODT pour le traitement de la migraine
- Dépôt de NDA pour le zavegepant, le premier antagoniste CGRP intranasal pour la migraine
- A dirigé la croissance de Biohaven depuis sa création jusqu'à sa vente de 13 milliards de dollars à Pfizer en mai 2022
Son expertise couvre plusieurs domaines thérapeutiques, y compris la neurologie, la psychiatrie, l'immunologie, la virologie, l'oncologie et l'immuno-oncologie. Le Dr Coric a terminé sa formation médicale à l'Université de Wake Forest et sa formation postdoctorale à la Yale School of Medicine.
Royalty Pharma (RPRX) hat Dr. Vlad Coric sofort in seinen Vorstand berufen. Dr. Coric, der derzeit Vorsitzender und CEO von Biohaven ist, bringt über 20 Jahre Erfahrung in der Arzneimittelentdeckung und klinischen Entwicklung von der Yale School of Medicine und Bristol-Myers Squibb mit.
Unter seiner Führung bei Biohaven erreichte Dr. Coric bedeutende Meilensteine, darunter:
- FDA-Zulassung und Markteinführung von Nurtec ODT zur Behandlung von Migräne
- Einreichung des NDA für Zavegepant, den ersten intranasalen CGRP-Antagonisten zur Behandlung von Migräne
- Leitete das Wachstum von Biohaven von der Gründung bis zum Verkauf an Pfizer für 13 Milliarden Dollar im Mai 2022
Seine Expertise erstreckt sich über mehrere therapeutische Bereiche, darunter Neurologie, Psychiatrie, Immunologie, Virologie, Onkologie und Immunonkologie. Dr. Coric absolvierte seine medizinische Ausbildung an der Wake Forest University und seine postdoktorale Ausbildung an der Yale School of Medicine.
- Appointment of experienced leader with proven track record of FDA approvals
- Direct experience in royalty funding transactions with RPRX
- Successfully led $13B company sale to Pfizer, demonstrating value creation ability
- Extensive expertise across multiple therapeutic areas
- None.
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology.
“I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric,” said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. “Vlad’s entrepreneurial approach and outstanding leadership skills, honed over a distinguished career in biopharma, will serve as tremendous assets to Royalty Pharma. In addition, Vlad brings notable experience in the royalty funding space, having completed multiple transactions with us during his tenure at Biohaven. We look forward to leveraging his scientific expertise and insights to advance our position as the leading partner funding innovation in life sciences.”
Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug candidate, zavegepant, as the first intranasal CGRP antagonist for ultra-rapid relief of migraine. During his tenure, Dr. Coric oversaw Biohaven’s impressive growth from its founding through its sale to Pfizer in May of 2022 for approximately
Dr. Coric has more than 20 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb prior to leading Biohaven. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neurology, psychiatry, immunology, virology, oncology and immuno-oncology. During his career, he has been involved in multiple drug development programs. Dr. Coric completed his postdoctoral internship, residency and fellowship at Yale School of Medicine, earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
What experience does Dr. Vlad Coric bring to Royalty Pharma's (RPRX) board?
What major achievements did Dr. Coric accomplish at Biohaven before joining RPRX's board?
How does Dr. Coric's appointment benefit Royalty Pharma (RPRX)?
What therapeutic areas does Dr. Coric specialize in for RPRX's board?
